Thursday, February 28, 2013
• Inviragen Inc., of Fort Collins, Colo., said it started the second stage of its ongoing Phase II study testing DENVax, its dengue vaccine, following review and recommendation by the data safety monitoring board.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.